G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal Article
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer.
Thomas A. Buchholz,Kelly K. Hunt,Amosson Cm,Susan L. Tucker,Eric A. Strom,McNeese,Aman U. Buzdar,S. E. Singletary,Gabriel N. Hortobagyi +8 more
TL;DR: Giving chemotherapy before radiation in lymph node-negative breast cancer did not compromise local control and given the concerns about increased distant metastases if radiation is given first, the chemotherapy-radiation sequence is recommended.
Journal ArticleDOI
Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Kelly K. Hunt,Cansu Karakas,Min Jin Ha,Anna Biernacka,Min Yi,Aysegul A. Sahin,Opoku Adjapong,Gabriel N. Hortobagyi,Melissa L. Bondy,Patricia A. Thompson,Kwok-Leung Cheung,Ian O. Ellis,Sarah S. Bacus,W. Fraser Symmans,Kim Anh Do,Khandan Keyomarsi +15 more
TL;DR: Cytoplasmic cyclin E identifies patients with the highest likelihood of recurrence consistently across different patient cohorts and subtypes of breast cancer using patient cohorts with distinct clinical and pathologic features.
Journal ArticleDOI
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
Young Kwang Chae,Erika Brown,Xiudong Lei,Amal Melhem-Bertrandt,Sharon H. Giordano,Jennifer K. Litton,Gabriel N. Hortobagyi,Ana M. Gonzalez-Angulo,Mariana Chavez-MacGregor +8 more
TL;DR: No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy, and ARB use may be associated with improved RFS.
Journal ArticleDOI
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Wendy A. Woodward,William E. Barlow,Reshma Jagsi,Thomas A. Buchholz,Steven Shak,Frederick L. Baehner,Timothy J. Whelan,Nancy E. Davidson,Nancy E. Davidson,James N. Ingle,Tari A. King,Peter M. Ravdin,C. Kent Osborne,Debasish Tripathy,Robert B. Livingston,Julie R. Gralow,Gabriel N. Hortobagyi,Daniel F. Hayes,Kathy S. Albain +18 more
TL;DR: This study found that higher recurrence scores were associated with increased LRR after adjustment for treatment, type of surgical procedure, and number of positive nodes, which suggests that the recurrence score may be used, along with accepted clinical variables, to assess the risk of LRR during radiotherapy decision-making.
Journal ArticleDOI
Radiographic evaluation of therapeutic response in bony metastases of breast cancer
TL;DR: Response to chemotherapy was evaluated in 50 previously untreated patients with bony metastases of breast cancer, with particular attention paid to the lytic areas.